Guidelines for Authors
'Psychotherapy and Psychosomatics' publishes research articles on clinical issues in medicine and psychiatry, with special reference to psychotherapy and psychosomatic research. The journal features editorials and review articles on current and controversial issues; innovations (both in terms of conceptualization and pilot studies); case management articles (biopsychosocial management in clinical medicine); clinical notes; letters to the editor (both comments on published articles and preliminary research).
Submission
Only papers written in English are considered and should be submitted using the online submission website at:
www.karger.com/pps
Should you experience any problems with your submission, please contact Giovanni A. Fava, MD Dipartimento di Psicologia Università di Bologna Viale Berti Pichat 5 I-40127 Bologna (Italia) E-Mail: giovanniandrea.fava@unibo.it
Conditions
All manuscripts are subject to editorial review. Manu scripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Psychotherapy and Psychosomatics' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
Conflict of Interest
All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed in the acknowledgement section of the paper, regardless of their potential relevance to the paper. In the cover letter to the editor, the corresponding author should certify that all forms of conflict of interest by all authors were clearly identified in the text. Authors of systematic reviews concerned with therapeutics are asked to report funding sources and conflicts of interest of the studies that were selected.
Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.
Full address:
The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.
Key words: Please supply 3-10 key words in English that reflect the content of the paper.
Abstract: Abstracts should be no longer than 250 words for regular articles, and no longer than 150 words for clinical notes. They should include the following information: Background: the problem that prompted the study and the purpose of the study; Methods: data sources, subjects, design, measurements, data analysis; Results: most important findings; Conclusions: implications, future directions. Abstracts for Special Articles do not need to be structured. Editorials, Case Management articles and Letters to the Editor should not have an abstract.
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.
Tables and illustrations:
Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180  223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author's name, and 'top' with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1200 dpi.
Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.-per page.
Data analysis:
Adequate description of statistical analysis should be provided, including the types of statistical tests and whether they were one-or two-tailed. Standard deviations, instead of standard errors of the mean, are preferred. All significant results must include the test value, degree(s) of freedom, and probability level. Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.
Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).
Author's Choice TM Karger's Author's Choice TM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www. Karger.com. The option is available for a one-time fee of CHF 3000.-, which is a permissible cost in grant allocation. More information can be found at www.karger.com/ authors_choice.
NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice TM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available at http://publicaccess.nih.gov/policy.htm
Disclaimer:
The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 
Call for Abstracts is now available!
This year's theme is "Stretching the Boundaries: From Mechanisms of Disease to Models of Health" which was selected because it cuts across specific domains of inquiry and promotes novel approaches to long-standing questions. The Program Committee encourages abstract submissions across all areas of psychosomatic medicine, but shows particular interest in submissions focusing on mechanisms and models of adaptive functioning and health promotion. The meeting will also feature new work in integrative medicine, pregnancy, bioinformatics, and illness in military populations.
Abstracts will be accepted through October 23. The easiest way to order: w w w.karger.com/motph29
Anxiety disorders are not uncommon and are often 'comorbid' with other forms of mental disorders. This publication provides an update on the origins and the causes of anxiety disorders and their related symptoms. Its focus is on neuroimaging and neuroinflammation and genetics as well as areas where an overlap may exist with abnormal cardiovascular physiology. Further it takes a closer look at the early phases of anxiety disorder and the potential effects of prolonged illness prior to diagnosis and also investigates recent research findings about the neuroimmunology of depression and the immunomodulatory effects of antidepressants. It also examines the neuroinflammatory hypothesis about anxiety disorders and concludes with the succinct but evidencebased and comprehensive reports on the value of pharmacological treatments used for generalized anxiety disorder, panic disorder, social anxiety disorder, posttraumatic stress disorder and obsessivecompulsive disorder. The topics covered in this publication will certainly make it essential reading for both novice and expert practitioners in psychiatric medicine, but its appeal should extend even further and include those researching the neuropsychobiology of anxiety or trying to improve our grasp of posttraumatic stress disorder or obsessive-compulsive disorder.
For academic medical faculty unfamiliar with national and international regulations, the prospect of initiating and managing a clinical trial can be intimidating. The development of protocols and case report forms, compliance with regulatory requirements, the monitoring of clinical trials as well as the responsibilities of documentation are just some of the tasks the sponsor-investigator is faced with. This book covers the entire spectrum of a clinical trial, reviewing the diff erent stages step by step: fi nancial planning, crucial aspects of trial design, the authorization process and, finally, documentation. Moreover, it contains helpful tips, a practical glossary, instructions and a large number of resources related to the relevant regulations and forms conforming to the 'International Conference on Harmonization and Good Clinical Practice' and the European legislation. This makes the publication at hand an essential 'cookbook' for both academic faculty new to clinical trials as well as seasoned sponsors-investigators. • JOURNAL
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Substance abuse and behavioral addictions
European Addiction Research is a unique international scientifi c journal for the rapid publication of innovative research covering all aspects of addiction and related disorders. Representing an interdisciplinary forum for the exchange of recent data and expert opinion, it refl ects the importance of a comprehensive approach to resolve the problems of substance abuse and addiction in Europe. Coverage ranges from clinical and research advances in the fi elds of psychiatry, biology, pharmacology and epidemiology to social, and legal implications of policy decisions. The goal is to facilitate open discussion among those interested in the scientifi c and clinical aspects of prevention, diagnosis and therapy as well as dealing with legal issues. An excellent range of original papers makes European Addiction Research the forum of choice for all.
